Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-11, Stock:JNJ, The news for the past five days is as follows:
2018-04-04: NEWS1: 5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Johnson & Johnson And Reminds Investors To Contact The Firm.NEWS2: EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Johnson & Johnson of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 9, 2018 – JNJ.NEWS3: NYSE trader: Here are the real risks to the U.S. economy.NEWS4: Allergan's Vraylar Meets Endpoints in Bipolar I Phase III.NEWS5: Allergan's Vraylar Meets Endpoints in Bipolar I Phase III.NEWS6: AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use.NEWS7: AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use.NEWS8: Johnson & Johnson’s Quarterly Revenue Trend in 2017.NEWS9: J&J Jury Set to Weigh Banker's Claims Baby Powder Caused Cancer.NEWS10: Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for April 05, 2018.NEWS11: Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for April 05, 2018.NEWS12: Johnson & Johnson’s Valuation in March 2018.NEWS13: Which Big Pharma CEOs Least Deserved Their Big Pay Increases?.NEWS14: Which Big Pharma CEOs Least Deserved Their Big Pay Increases?.NEWS15: Analysts’ Recommendations for Johnson & Johnson in March 2018.NEWS16: Which Big Pharma CEOs Least Deserved Their Big Pay Increases?.NEWS17: The boycott of Laura Ingraham’s Fox News show barely registered with consumers (with one exception).NEWS18: The boycott of Laura Ingraham’s Fox News show barely registered with consumers (with one exception).NEWS19: Smith & Nephew Names Namal Nawana CEO - Quick Facts.NEWS20: Smith & Nephew Names Namal Nawana CEO - Quick Facts.
2018-04-05: NEWS1: Corrected: J&J loses trial over claims linking cancer to asbestos in talc.NEWS2: UPDATE 2-J&J loses trial over claims linking cancer to asbestos in talc.NEWS3: J&J Ordered to Pay $37 Million Over Banker's Talc Cancer Claims.NEWS4: J&J Must Pay Millions Over Banker's Baby Powder Cancer Claim.NEWS5: J&J Ordered to Pay $37 Million Over Banker's Talc Cancer Claims.NEWS6: FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus.NEWS7: FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus.NEWS8: Wall Street Brushes Off Trade War Fears: Top 5 Gainers.NEWS9: Wall Street Brushes Off Trade War Fears: Top 5 Gainers.NEWS10: FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus.NEWS11: 5 Dividend Growth Stocks With Upside To Analyst Targets.NEWS12: 5 Dividend Growth Stocks With Upside To Analyst Targets.NEWS13: 3 Emerging Technologies Set to Transform the Pharma World.NEWS14: Johnson & Johnson’s Business Segments in 2017.NEWS15: Alkermes' Bad News Could Be Good News for Johnson & Johnson.NEWS16: Alkermes' Bad News Could Be Good News for Johnson & Johnson.NEWS17: Alkermes&apos; Bad News Could Be Good News for Johnson & Johnson.
2018-04-06: NEWS1: NJ Man Wins $37 Million in J&J Baby Powder Case.NEWS2: Stocks dive as US proposes more China tariffs; Dow falls 620.NEWS3: Stocks skid again after US proposes more China tariffs.NEWS4: APRIL 9 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Johnson & Johnson And Reminds Investors To Contact The Firm.NEWS5: The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson.NEWS6: The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson.NEWS7: 4 Drug/Biotech Stocks to Buy Ahead of World Health Day.NEWS8: 4 Drug/Biotech Stocks to Buy Ahead of World Health Day.NEWS9: MARKETS: Watch out for the 'Kudlow Put' round 2 and the Chinese tariff tantrum.NEWS10: The Top 5 Johnson & Johnson Shareholders (JNJ).NEWS11: Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?.NEWS12: Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?.NEWS13: 4 Drug/Biotech Stocks to Buy Ahead of World Health Day.NEWS14: The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson.NEWS15: Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?.NEWS16: These Alphabet-Backed Biotech Startups Went Public In 1Q18.NEWS17: JNJ EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Johnson & Johnson and a Lead Plaintiff Deadline of April 9, 2018.NEWS18: 3 Emerging Technologies Set to Transform the Pharma World.NEWS19: 3 Emerging Technologies Set to Transform the Pharma World.NEWS20: J&J, Imerys Ordered To Pay $37 Mln In Case Over Talc Cancer Risks.NEWS21: J&J, Imerys Ordered To Pay $37 Mln In Case Over Talc Cancer Risks.NEWS22: J&J loses trial over claims linking cancer to asbestos in talc.
2018-04-09: NEWS1: Billionaire Ken Fisher’s Favorite Dividend Stocks.NEWS2: How Johnson & Johnson Stock Performed in 1Q18.NEWS3: Glancy Prongay & Murray LLP Reminds Investors of the April 9, 2018 Deadline in the Class Action Lawsuit Against Johnson & Johnson.NEWS4: Pharma’s Latest: Mergers and Acquisitions in 1Q18.NEWS5: DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Johnson & Johnson And Reminds Investors To Contact The Firm.NEWS6: DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Johnson & Johnson of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 9, 2018 – JNJ.NEWS7: 3 Reasons This Clinical-Stage Biotech Is an Incredible Bargain.
2018-04-10: NEWS1: FDA Approves First Contact Lens With Light-adaptive Technology.NEWS2: FDA Approves First Contact Lens With Light-adaptive Technology.NEWS3: Why J&J’s Fallen Stock Is Still Too Pricey.NEWS4: DGRO, JNJ, AAPL, MSFT: ETF Inflow Alert.NEWS5: DGRO, JNJ, AAPL, MSFT: ETF Inflow Alert.NEWS6: Google to power Georgia data center with solar energy.NEWS7: How Merck & Co. Stock Performed in 1Q18.NEWS8: Analyst Recommendations for Teva Pharmaceutical in April 2018.NEWS9: Analyst Recommendations for Valeant Pharmaceuticals in April.NEWS10: Novartis and Other Drug Stocks With FDA Catalysts in April.NEWS11: Novartis and Other Drug Stocks With FDA Catalysts in April.NEWS12: Wired News – Johnson & Johnson to Pay Compensatory Damages over Claims Linking Cancer to Asbestos in Talc.NEWS13: Novartis and Other Drug Stocks With FDA Catalysts in April.

Answer: Decrease